ASCO Welcomes Tobacco Bill

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

The American Society of Clinical Oncology (ASCO) is backing legislation (H.R. 1097) that would give the Food and Drug Administration (FDA) the authority to regulate tobacco products. The legislation explicitly states that nicotine should be

The American Society of Clinical Oncology (ASCO) is backinglegislation (H.R. 1097) that would give the Food and Drug Administration (FDA) the authority to regulate tobacco products. The legislationexplicitly states that nicotine should be regulated as a drug, and tobaccoproducts as drug delivery devices. The legislation also gives the FDA theauthority to regulate tobacco product advertising and promotion. Reps. GregGanske (R-Iowa), John Dingell (D-Mich), and Henry Waxman (D-Calif) are theprimary sponsors.

"We greatly appreciate the consistent leadership Reps.Ganske, Dingell, and Waxman provide on behalf of the federal regulation oftobacco products," said an ASCO statement. "Smoking accounts for atleast 30% of all cancer deaths, is a major cause of heart disease, and isassociated with conditions ranging from colds and gastric ulcers to chronicbronchitis, emphysema, and cerebrovascular disease."

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content